Aurobindo expects Sandoz buy to make it second-largest generics firm in US

Aurobindo Pharma says it expects to become the second-largest generic drugs entity by prescriptions in America, once it completes the acquisition process involving the dermatology and oral solids business of Sandoz.

The Hyderabad-based company is at fifth place in prescription sales, next to Indian counterpart Lupin, in the US.

After the acquisition, Aurobindo's market share in the US will be 8.6 per cent, higher than Mylan (6.4) and Lupin (5.7) in terms of number of prescriptions dispensed. Teva is top with 14.3 per cent. 

Aurobindo signed the deal with Sandoz in September 2018, for upfront payment of $900 million. The